Venous thromboembolism (VTE) is a life-threatening complication in children with serious underlying conditions such as heart defects or cancer. Treatment or prevention of thrombosis poses an additional challenge in everyday clinical practice. A therapy using the active ingredient rivaroxaban specifically tailored to children was successfully tested for the first time in 2020. Now, long-term data confirm the benefits of this drug treatment even for extended use. The study was conducted by an international research team led by MedUni Vienna and has been published in the journal “The Lancet Haematology”.
The long-term data collected by the research team led by Christoph Male from the Department of Pediatrics and Adolescent Medicine at MedUni Vienna provides the first reliable evidence for extended…